GT
SGMO

Glenmede Trust’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Glenmede Trust’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-50,177
Closed -$290K – 2666
2016
Q2 		$290K Sell
50,177
-950
-2% -$6.05K ﹤0.01% 1079
2016
Q1 		$309K Hold
51,127
– – ﹤0.01% 1045
2015
Q4 		$466K Sell
51,127
-13,859
-21% -$107K ﹤0.01% 942
2015
Q3 		$366K Buy
64,986
+36,000
+124% +$297K ﹤0.01% 1023
2015
Q2 		$321K Sell
28,986
-7,000
-19% -$90.3K ﹤0.01% 1101
2015
Q1 		$563K Hold
35,986
– – ﹤0.01% 911
2014
Q4 		$546K Buy
35,986
+2,000
+6% +$24.3K ﹤0.01% 909
2014
Q3 		$365K Sell
33,986
-1,000
-3% -$13.1K ﹤0.01% 980
2014
Q2 		$533K Hold
34,986
– – ﹤0.01% 847
2014
Q1 		$632K Sell
34,986
-1,200
-3% -$23.1K 0.01% 808
2013
Q4 		$502K Sell
36,186
-800
-2% -$9.21K 0.01% 852
2013
Q3 		$387K Hold
36,986
– – ﹤0.01% 899
2013
Q2 		$288K Buy
+36,986
New +$323K ﹤0.01% 965

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Glenmede Trust's SGMO Position: Q3 2016 in Review

Glenmede Trust sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2016, closing a stake of 50,177 shares — an estimated $290K sold.

Glenmede Trust first reported a position in SGMO in Q2 2013 and held it in 13 quarters. The position peaked at $632K in Q1 2014. 124 funds tracked by Wall St. Rank hold SGMO as of Q3 2016.

  • Glenmede Trust reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2016 after selling out during the quarter.
  • Glenmede Trust sold 50,177 SANGAMO THERAPEUTICS INC shares in Q3 2016, an estimated $290K.
  • Glenmede Trust first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 13 quarters.
  • Glenmede Trust's SANGAMO THERAPEUTICS INC position peaked at $632K in Q1 2014.
  • 124 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2016.

Based on Glenmede Trust's 13F filing for Q3 2016, filed 14 Nov 2016.